Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (Faslodex, Fulvestrant)

Cancer Research

Volumn 64, Issue 11, 2004, Pages 4030-4039

  Bouker, Kerrie B ^a   Skaar, Todd C ^a,c   Fernandez, David R ^a   O'Brien, Kerry A ^a   Riggins, Rebecca B ^a   Cao, Donghua ^c   Clarke, Robert ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; DOXORUBICIN; ESTROGEN RECEPTOR; FULVESTRANT; INTERFERON REGULATORY FACTOR 1; LUCIFERASE; MESSENGER RNA;

APOPTOSIS; ARTICLE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOLYSIS; CYTOSTASIS; DOSE RESPONSE; DRUG RESISTANCE; GENETIC TRANSFECTION; HORMONAL REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; REPORTER GENE; RIBONUCLEASE PROTECTION ASSAY; RNA EXTRACTION;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; HUMANS; INTERFERON REGULATORY FACTOR-1; PHOSPHOPROTEINS; RECEPTORS, ESTROGEN;

EID: 2542531457     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3602     Document Type: Article

References (68)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451-67.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;399:1-15.
3. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002;20:3317-27.
4. Ravdin P. Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer. Lancet 2002;359:2126-7.
5. Chlebowski RT, Col N, Winer EP, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002;20:3328-43.
6. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001;53:25-71.
7. Robertson JFR. ICI 182,780 (Fulvestrant): the first oestrogen receptor down-regulator: current clinical data. Br J Cancer 2001;85(Suppl 2):11-14.
8. Howell A, DeFriend D, Robertson JFR, Blamey RW, Walton P. Response to a specific antioestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet 1995;345:29-30.
9. Howell A, Robertson JF, Quaresma AJ, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-403.
10. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386-95.
11. Wakeling AE. The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res Treat 1993;25:1-9.
12. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 1992;89:4037-41.
13. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 1990;87:6883-7.
14. Wakeling AE, Bowler J. Novel antioestrogens without partial agonist activity. J Steroid Biochem 1988;31:645-53.
15. Clarke R, Liu M, Bouker KB, et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003;22:7316-39.
16. Fisher B, Costanfino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst (Bethesda) 1998;90:1371-88.
17. Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst (Bethesda) 2003;95:160-5.
18. Clarke R, Brünner N. Acquired estrogen independence and antiestrogen resistance in breast cancer: estrogen receptor-driven phenotypes? Trends Endocrinol Metab 1996;7:25-35.
19. Gu Z, Lee RY, Skaar TC, et al. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-κB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780). Cancer Res 2002;62:3428-37.
20. Tanaka N, Ishihara M, Kitagawa M, et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994;77:829-39.
21. Tanaka N, Ishihara M, Taniguchi T. Suppression of c-myc or fosB-induced cell transformation by the transcription factor IRF-1. Cancer Lett 1994;83:191-6.
22. Yim JH, Wu SJ, Casey MJ, Norton JA, Doherty GM. IFN regulatory factor-1 gene transfer into an aggressive, nonimmunogenic sarcoma suppresses the malignant phenotype and enhances immunogenicity in syngeneic mice. Hokkaido Igaku Zasshi 1997;71:509-16.
23. Sillman CL, Sever CE, Pallavicini MG, et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993;259:968-70.
24. Tamura G, Ogasawara S, Hishizuka S, et al. Two distinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. Cancer Res 1996;56:612-5.
25. Nozawa H, Oda E, Nakao K, et al. Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev 1999;1-3:1240-5.
26. Tanaka N, Ishihara M, Lamphier MS, et al. Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature 1996;382:816-818.
27. Tamura T, Ishihara M, Lamphier MS, et al. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 1995;376:596-9.
28. Moro A, Santos A, Arana MJ, Perea SE. Activation of the human p27(Kip1) promoter by IFNα 2b. Biochem Biophys Res Commun 2000;269:31-4.
29. Sanceau J, Hiscott J, Delattre O, Wietzerbin J. IFN-β induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene 2000;19:3372-83.
30. Suk K, Chang I, Kim Y, et al. Interferon γ (IFNγ) and tumor necrosis factor a synergism in ME-180 cervical cancer cell apoptosis and necrosis: IFNγ inhibits cytoprotective NF-κB through STAT1/IRF-1 pathways. J Biol Chem 2001;276:13153-9.
31. Chow W, Fang J, Yee J The IFN regulatory factor family participates in regulation of Fas ligand gene expression in T cells. J Immunol 2000;164:3512-8.
32. Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 1994;32:39-47.
33. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of randomised trials. Lancet 1998;352:930-42.
34. Berry D, Muss H, Thor A, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-negative breast cancer. J Clin Oncol 2000;18:3471-9.
35. Harroch S, Revel M, Chebath J. Induction by interleukin-6 of interferon regulatory factor 1 (IRF-1) gene expression through the palindromic interferon response element pIRE and cell type-dependent control of IRF-1 binding to DNA. EMBO J 1994;13:1942-9.
36. Doherty GM, Boucher L, Sorenson K, Lowney J. Interferon regulatory factor expression in human breast cancer. Ann Surg 2001;233:623-9.
37. Brooks SC, Locke ER, Soule HD. Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem 1973;248:6251-3.
38. Chalbos D, Vignon F, Keydar I, Rochefort H. Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D). J Clin Endocrinol Metab 1982;55:276.
39. Brünner N, Boulay V, Fojo A, Freter C, Lippman ME, Clarke R. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res 1993;53:283-90.
40. Brünner N, Boysen B, Jirus S, et al. MCF7/LCC9: an antiestrogen resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early crossresistance to the non-steroidal antiestrogen tamoxifen. Cancer Res 1997;57:3486-93.
41. Pratt MAC, Bishop TE, White D, et al. Estrogen withdrawal-induced NF-κB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol Cell Biol 2003;23:6887-900.
42. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst (Bethesda) 2001;93:684-90.
43. Clarke R, Brünner N, Katzenellenbogen BS, et al. Progression from hormone dependent to hormone independent growth in MCF-7 human breast cancer cells. Proc Natl Acad Sci USA 1989;86:3649-53.
44. LaBorda J. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 1991;19:3998.
45. Clarke R, Brünner N, Katz D, et al. The effects of a constitutive production of TGF-α on the growth of MCF-7 human breast cancer cells in vitro and in vivo. Mol Endocrinol 1989;3:372-80.
46. Sledz CA, Holko M, De Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-9.
47. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003;34:263-4.
48. Vindelov LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323-7.
49. Lindner DJ, Ma X, Hu J, Karra S, Kalvakolanu DV. Thioredoxin reductase plays a critical role in IFN retinoid-mediated tumor-growth control in vivo. Clin Cancer Res 2002;8:3210-8.
50. Del Bino G, Darzynkiewicz Z, Degraef C, Mosselmans R, Fokan D, Galand P. Comparison of methods based on annexin-V binding, DNA content or TUNEL for evaluating cell death in HL-60 and adherent MCF-7 cells. Cell Prolif 1999;32:25-37.
51. Gad S and Weil CS. Statistics and experimental design for toxicologists. Caldwell, NJ: Telford Press; 1988.
52. Kano A, Haruyama T, Akaike T, Watanabe Y. IRF-1 is an essential mediator in IFN-γ-induced cell cycle arrest and apoptosis of primary cultured hepatocytes. Biochem Biophys Res Commun 1999;257:672-7.
53. Howell A, DeFriend DJ, Robertson JFR, et al. Pharmacokinetics, pharmacological and anti-tumor effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 1996;74:300-8.
54. Paik S, Bryant J, Park C, et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst (Bethesda) 1998;90:1361-70.
55. Trock BJ, Leonessa F, Clarke R. Mulfidrug resistance in breast cancer: a meta analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst (Bethesda) 1997;89:917-31.
56. Carroll JS, Prall OW, Musgrove EA, Sutherland RL. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of pi 30-E2F4 complexes characteristic of quiescence. J Biol Chem 2000;275:38221-9.
57. Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990;5:893-9.
58. Mandlekar S, Hebbar V, Christov K, Kong AN. Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines. Cancer Res 2000;60:6601-6.
59. Kurokawa H, Nishio K, Fukumoto H, et al. Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells. Oncol Rep 1999;6:33-7.
60. Tamura T, Ueda S, Yoshida M, Matsuzaki M, Mohri H, Okubo T. Interferon-γ induces ICE gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line. Biochem Biophys Res Commun 1996;229:21-6.
61. Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995;267:891-3.
62. Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996;56:4791-8.
63. Liang Y, Yan C, Schor NF. Apoptosis in the absence of caspase 3. Oncogene 2001;20:6570-8.
64. Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A. Interferon-γ treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 2000;60:5673-80.
65. Kondo T, Minamino N, Nagamura-Inoue T, Matsumoto M, Taniguchi T, Tanaka N. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Oncogene 1997;15:1275-81.
66. Skaar TC, Prasad SC, Sharaeh S, Lippman ME, Brunner N, Clarke R. Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells. J Steroid Biochem Mol Biol 1998;67:391-402.
67. Brankin B, Skaar TC, Trock BJ, Berris M, Clarke R. Autoantibodies to numatrin: an early predictor for relapse in breast cancer. Cancer Epidemiol Biomark Prev 1998;7:1109-15.
68. Zhu Y, Bouker KB, Skaar TC, et al. High throughput tissue microarray study of antiestrogen related genes in human breast cancers [abstract]. In: Proceedings of the 85th Annual Meeting of the Endocrine Society 2003; p.140.